Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells.

ABSTRACT: Dipeptidyl peptidase-4 (DPP-4) is a critical molecule for the metabolism of incretins. In addition, DPP-4 is known as CD26, the receptor of T cells, and plays important role in activation of T cells. Recently, DPP-4 inhibitors (DPP4i) are reported to have several immunologic effects beyond glycemic control. DPP4i seem to have anti-inflammatory effects in patients with type 2 diabetes. This might be direct effects on T cells. However, the close mechanism is not clear. To evaluate the possibility, we performed ex vivo assays by using primarily human CD4⁺ T cells (CD4) and CD8⁺ T cells (CD8). We purified primary naïve CD4 and CD8 from human peripheral blood. Then, we evaluated the effect of DPP4i on the proliferation of naïve T cells and the cytokine production in

SUBMITTER: Kitagawa N 

PROVIDER: S-EPMC6160731 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature